pharmaphorum

JANUARY 27, 2021

AstraZeneca is playing catch up with Eli Lilly and Regeneron with its antibody therapy for COVID-19, but aims to narrow the gap with the help of decentralised clinical trial specialist Care Access Research. The two antibodies were discovered by Vanderbilt University Medical Center and licensed to AZ in June 2020.

Antibody 94

Antibody Clinical Trials Clinical Trials Trials 94

Worldwide Clinical Trials

OCTOBER 14, 2024

Fortunately, advances in clinical research are providing hope for better treatments and outcomes. With the support of global networks like ours at Worldwide Clinical Trials (Worldwide), autoimmune and bone health research is accelerating, providing new solutions to patients around the world.

Research 130

Research Clinical Trials Clinical Trials Immune Response 130

Pharmaceutical Technology

JANUARY 17, 2023

The Joint Cancer Immunotherapy Clinical Research Unit of the Hospital Universitario 12 de Octubre and the Spanish National Cancer Research Center (CNIO) created the STAb-T therapy led by Dr Luis Álvarez-Vallina and the Josep Carreras Leukaemia Research Institute team Dr Pablo Menéndez and Dr Diego Sánchez-Martínez.

Development 276

Development Gene Therapy Antibody Gene 276

Worldwide Clinical Trials

JUNE 21, 2024

The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinical researchers to discuss the latest advancements and challenges in oncology research. Currently, there are 12 approved ADC drugs, and several hundred more are in the development pipeline.

Antibody 162

Antibody Clinical Trials Clinical Trials In-Vitro 162

XTalks

MAY 2, 2022

Lecanemab, the product of Phase IIb clinical research completed by BioArctic and collaborator Eisai, is one therapy making strides this year for Alzheimer’s disease. This year, the monoclonal antibody lecanemab is approaching final stages of investigation as a treatment for targeting the A? Next Stages in Clinical Research.

Clinical Trials 98

Clinical Trials Clinical Trials Antibody Trials 98

Pharmaceutical Technology

AUGUST 16, 2022

A first-in-class Trop-2 directed antibody-drug conjugate, Trodelvy is made with a hydrolyzable linker joined to a topoisomerase I inhibitor payload, SN-38. Gilead Sciences Oncology Clinical Research senior vice-president Bill Grossman said: “Trodelvy is approved for second-line metastatic TNBC in over 35 countries. “We

Medicine 255

Medicine Marketing Development Clinical Development 255

BioPharma Reporter

OCTOBER 27, 2020

The clinical research solutions firm is joining forces with pharma giant Eli Lilly to manage mobile research of the monoclonal antibody LY-CoV555.

Research 98

Research Antibody Clinical Research Trials 98

Pharmaceutical Technology

MAY 12, 2023

The collaboration will use the integrated drug creation platform of Absci and the clinical immunology datasets from the Kennedy Institute to identify antibodies to immune-mediated inflammatory diseases and autoimmune conditions with unprecedented speed.

Development 130

Development Antibody Immune Response Genome 130

Cloudbyz

AUGUST 2, 2024

The field of oncology has seen significant progress in recent years, with the development of novel therapies and advancements in clinical research. Targeted Therapies and Immunotherapies One of the most notable trends in cancer drug research is the development of targeted therapies and immunotherapies.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

XTalks

JUNE 11, 2024

Askanase shares her insights on the crucial role of patient voices in shaping research, offering hope for new, more effective lupus treatments. This magazine immerses you in a world where industry leaders, patient advocates and top researchers converge to provide the most insightful perspectives on clinical trials.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Roots Analysis

AUGUST 14, 2023

Antibodies are key components of the immune system that bind to specific markers on cells or tissues, thereby offering first line of defense against multiple disorders. The novel antibody therapies include different classes of antibodies, that are responsible for killing or inhibiting disease-causing agents.

Antibody 52

Antibody Development Marketing Engineer 52

XTalks

JULY 25, 2022

Later lines of treatment can include monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates (ADCs). XTALKS WEBINAR: Discussing the Concerns within Clinical Research in Oncology and In-Home Healthcare. ADCs consist of an antibody attached to a cytotoxin that is delivered to targeted cells.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

XTalks

DECEMBER 10, 2024

Recent advancements in ITP treatments include CM313, an anti-CD38 monoclonal antibody that achieved a 95.5 This aligns with previous studies, reinforcing its potential as a well-tolerated treatment option. percent platelet response in a study published in The New England Journal of Medicine.

Trials 104

Trials Protein Clinical Development Drugs 104

XTalks

MARCH 17, 2025

This system captures and enriches circulating tumor cells (CTCs) and related biomarkers from patient blood samples using a physical, antigen-independent method offering an alternative to conventional antibody-based techniques.

Production 71

Production Manufacturing DNA Genetics 71

The Pharma Data

NOVEMBER 22, 2020

FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies with Pandion Therapeutics (Pandion). We now have a pipeline of undisclosed therapeutic partnerships nearing clinical research.

Antibody 52

Antibody Immune Response Engineer Protein 52

Delveinsight

NOVEMBER 26, 2020

Genmab discards antibody-drug conjugate after the early-phase fiasco. Genmab is ditching an antibody-drug conjugate after it flunked the mark in early-phase trials. The drug is presently delivered intravenously, so an inhaled version could make it possible for treating patients outside of a hospital or clinic. Clancy, M.D.,

Antibody 79

Antibody Trials Drugs Engineer 79

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccine 75

Vaccine Vaccination Immune Response Containment 75

Roots Analysis

MARCH 24, 2022

You may also be interested in the following titles: Continuous Manufacturing (Small Molecules and Biologics) Market Subcutaneous Biologics, Technologies and Drug Delivery Systems Market Antibody Discovery Services and Platforms Market. Our Social Media Platform. Web: [link]. LinkedIn: [link]. Twitter: [link].

Clinical Research 52

Clinical Research Development Research Drug Delivery Systems 52

XTalks

JANUARY 22, 2025

seroresponse rate indicating the proportion of participants achieving antibody levels above a predefined protective threshold sustained one year after vaccination. One year post-vaccination, antibody levels remained strong, with geometric mean titers well above the required protective threshold. The findings reveal a remarkable 98.3%

Immune Response 59

Immune Response Vaccine Vaccination Trials 59

pharmaphorum

SEPTEMBER 15, 2020

Humanigen is hoping for emergency use authorisation in the US for an antibody to treat severe COVID-19 before the end of 2020, and has teamed up with Swiss contract manufacturer Lonza to make sure it can meet demand. Lilly also has studies on the go for LY3127804, an investigational antibody targeting angiopoietin 2 (Ang2).

Drugs 97

Drugs Antibody Contract Manufacturing Immune Response 97

XTalks

DECEMBER 13, 2024

Blenrep is an antibody-drug conjugate (ADC) created by linking a B-cell maturation antigen (BCMA)-targeting monoclonal antibody to a potent cytotoxic agent, auristatin F, using a stable, non-cleavable linker technology. A day before GSKs announcement, Johnson & Johnson also released two promising clinical trial results.

Antibody 99

Antibody In-Vivo Trials In-Vitro 99

XTalks

DECEMBER 31, 2024

Imlifidase is an enzyme that works by cleaving immunoglobulin G (IgG) antibodies, thereby halting the immune-mediated damage that characterizes GBS. The first-in-class IgG cleaving enzyme has shown promise in other applications, including kidney transplantation and antibody-mediated rejection.

Life Science 52

Life Science Antibody Clinical Trials Clinical Trials 52

XTalks

OCTOBER 23, 2024

Otsuka Pharmaceutical has announced positive interim results from its Phase III clinical trial for sibeprenlimab. Sibeprenlimab, which has a Breakthrough Therapy designation, is a monoclonal antibody that blocks APRIL ( A PR oliferation- I nducing L igand), a critical step in the immune cascade contributing to IgAN.

Trials 101

Trials Clinical Trials Clinical Trials Antibody 101

XTalks

FEBRUARY 12, 2025

Similarly, Mediar Therapeutics entered a global licensing agreement with Eli Lilly to advance MTX-463, a first-in-class human IgG1 antibody that neutralizes WISP1-mediated fibrotic signaling, into a Phase II trial.

Clinical Trials 66

Clinical Trials Clinical Trials Trials FDA Approval 66

Velocity Clinical Research

AUGUST 8, 2024

It’s been just over a year since the monoclonal antibody Lecanemab received traditional approval from the FDA as a treatment for Alzheimer’s disease. He’s quick to note that developments like Lecanemab wouldn’t be possible without clinical trial participants, “Nothing happens nowadays without clinical research.

Clinical Trials 105

Clinical Trials Clinical Trials Genetics Clinical Research 105

XTalks

DECEMBER 28, 2023

BillionToOne will provide its UNITY Fetal Antigen Non-invasive Prenatal Test Clinical Trial Assay (UNITY Fetal Antigen CTA) as a critical screening tool to determine the eligibility of pregnant participants. Nipocalimab is an investigational monoclonal antibody that targets the neonatal Fc receptor.

Trials 97

Trials Clinical Trials Clinical Trials Antibody 97

Rethinking Clinical Trials

JANUARY 17, 2024

The first monoclonal antibody (mABs) treatment for treatment of COVID-19 was approved in November 2020. UPMC built upon the success of the Remdesivir lottery and in December 2020, UPMC began infusing monoclonal antibodies across 45 UPMC locations.          Speaker Erin K.

Clinical Trials 135

Clinical Trials Clinical Trials Antibody Trials 135

pharmaphorum

OCTOBER 21, 2022

The acquisition of DJS Antibodies, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins – such as G protein-coupled receptors (GPCRs) – will extend AbbVie’s present discovery research capabilities, through DJS’ proprietary HEPTAD platform.

Antibody 59

Antibody Protein Research Medicine 59

XTalks

JANUARY 17, 2024

In this Xtalks Spotlight edition, Xtalks spoke with two oncology clinical research experts from Fortrea , Laura Vidal, MD, Medical Head of Oncology, EU (European Union), and Ken Morrison, PhD, Global Head of Strategic Delivery & Growth Oncology.

Clinical Trials 124

Clinical Trials Clinical Trials Trials Gene Therapy 124

pharmaphorum

SEPTEMBER 29, 2020

Elezanumab is a monoclonal antibody that binds selectively to repulsive guidance molecule, which is known to inhibit regeneration of neurons and functional recovery following central nervous system damage. The regulator has also granted it orphan status, which cuts development costs and potentially boosts profits if approved.

Drugs 105

Drugs Development Antibody Clinical Research 105

XTalks

APRIL 1, 2025

Related: Niktimvo (Axatilimab) Approved as First-in-Class Therapy for Chronic GVHD More on Itolizumabs Clinical Data Itolizumab is a humanized anti-CD6 monoclonal antibody that targets the CD6-ALCAM pathway involved in T cell activation and trafficking. The risk limits the number and type of patients who receive HSCT.

52

52

XTalks

JULY 26, 2024

Merck recently announced encouraging topline results from its Phase IIb/III trial ( MALRI ) of clesrovimab (MK-1654), an investigational monoclonal antibody aimed at preventing respiratory syncytial virus (RSV) in infants. However, advancements in monoclonal antibody technology have opened new avenues for RSV prevention and treatment.

Antibody 59

Antibody Vaccine Vaccination Trials 59

pharmaphorum

APRIL 7, 2021

billion DKK ($672 million) from AbbVie after the companies struck an R&D deal to research epcoritamab, a bispecific antibody targeting CD3 and CD20 that the biotech developed in-house. Genmab has four technology platforms to draw from, with the most established being bispecific antibodies which target two receptors at once.

Antibody 92

Antibody Life Science Development Drugs 92

XTalks

DECEMBER 5, 2024

Unlike the reigning blockbuster GLP-1 drugs on the market namely Novo Nordisks Wegovy (semaglutide) and Eli Lillys Zepbound (tirzepatide), the latter of which is a dual agonist of the GLP-1 and GIP receptors Amgens MariTide is an antibody-peptide conjugate that combines a GLP-1 receptor agonist (consisting of two peptides that mimic the GLP-1 hormone) (..)

Trials 104

Trials Drugs Clinical Trials Clinical Trials 104

pharmaphorum

JANUARY 5, 2022

The results of the CORAL-BOOST are only in a few patients, but showed strong increases in neutralising antibody levels when Gritstone’s shot given as a booster after two doses of AstraZeneca’s Vaxzevria given as a primary course.

Protein 126

Protein Vaccination Vaccine Immune Response 126

Pharmaceutical Technology

SEPTEMBER 10, 2008

.” New projects we have been involved with have helped the company to accelerate its development in the field of pre-clinical research. Now the company is a GLP-certified contract research organisation that focuses on three main domains. IS: We mainly recruit our staff from local universities and special high schools.

In-Vitro 100

In-Vitro Genotoxicity In-Vivo Development 100